Head-to-head evidence
Albuterol Sulfate (Provenetil-HFA) vs salbutamol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Albuterol Sulfate (Provenetil-HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
Proventil-HFA serves here as the active reference product against which the investigational albuterol-HFA is compared in a secondary analysis, while the trial's main comparison is between the investigational product and placebo; no results have been posted yet.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
salbutamol
Developed by GlaxoSmithKline
NCT03528577 · Phase 3 · completed
The study randomized 128 participants in a quadruple-blind, four-period crossover design with active and placebo comparators. However, its primary endpoint was a pharmacodynamic surrogate rather than a hard clinical outcome. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: June 2027 · NCT06473779 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuterol Sulfate (Provenetil-HFA)'s landscape · salbutamol's landscape